Study
| Phase 3, randomized, open-label, noninferiority trial (EMERALD) |
| HER2+ locally advanced/metastatic breast cancer |
| Eribulin + trastuzumab + pertuzumab vs. Taxane (docetaxel or paclitaxel) + trastuzumab + pertuzumab |
Efficacy
| ORR: 76.8% vs. 75.2% (eribulin + TP vs. taxanes + TP) |
| mPFS: 14.0 mos vs. 12.9 mos (HR: 0.95 [0.76–1.19]) |
| mOS: NR vs. 65.3 mos (HR: 1.09 [0.76–1.58]) |
| QoL maintenance at 6 mos: 62.7% vs. 43.8% |
Safety
| Grade ≥3 AEs: ~60% in both groups |
| Eribulin: more neutropenia (61.6%), peripheral neuropathy (grade ≥3: 9.8%) |
| Taxane: more infusion reactions, diarrhea, edema, skin AEs |
J Clin Oncol 2025;43:1302-13
http://doi.org/10.1200/JCO-24-01888
Reviewed by Ulas D. Bayraktar, MD on Apr 22, 2025
